Merck, known as MSD outside the United States and Canada, has opened a new $1 billion, 225,000-square-foot vaccine manufacturing facility at its Durham, North Carolina, site. This expansion is part of Merck’s broader $12 billion investment in U.S. manufacturing and research and development since 2018. The initiative focuses on strengthening domestic production capabilities and job … Merck Launches $1 Billion Vaccine Facility in North Carolina, Boosting U.S. Manufacturing and Job Creation Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.